Reviva Pharmaceuticals Holdings is a clinical-stage biopharmaceutical company. Co.'s pipeline has two drug candidates, brilaroxazine (RP5063) and RP1208. Co.'s main drug candidate, brilaroxazine, is in clinical development and is intended to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis. Furthermore, brilaroxazine is for two respiratory indications, pulmonary arterial hypertension and idiopathic pulmonary fibrosis. Co.'s RP1208 is for the treatment of depression and obesity. The RVPH average annual return since 2018 is shown above.
The Average Annual Return on the RVPH average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether RVPH average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the RVPH average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free RVPH Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
